文献速递其他结缔组织病

抗皮质蛋白自身抗体与成人肌炎关键临床特征相关,但在幼年肌炎中罕见

Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis.
PubMed 文献 · Arthritis Rheumatol · 2021-12-26

该纵向队列研究采用酶联免疫吸附试验检测670例成人肌炎、343例幼年肌炎及202例成人健康对照和90例幼年健康对照的抗皮质蛋白自身抗体滴度,比较各组患病率及临床特征。结果发现抗皮质蛋白抗体在成人皮肌炎中更常见(15%),尤其合并抗Mi-2(24%)或抗NXP-2(23%)抗体者,并与吞咽困难、间质性肺病相关;幼年肌炎中患病率(2%)与健康对照(4%)无差异。

要点

  • 抗皮质蛋白抗体在成人皮肌炎中患病率15%,合并抗Mi-2或抗NXP-2时更高。
  • 成人肌炎中该抗体与吞咽困难、间质性肺病及抗Ro52/抗NT5c1a共存相关。
  • 幼年肌炎中该抗体罕见(2%),与健康对照无差异,但阳性者「机械手」更多、住院次数更高、峰值肌酸激酶更低。

核心结论

  • 抗皮质蛋白自身抗体在成人皮肌炎中患病率升高,尤其合并抗Mi-2或抗NXP-2抗体者。
  • 成人肌炎中抗皮质蛋白抗体与吞咽困难和间质性肺病相关。
  • 幼年肌炎中抗皮质蛋白抗体罕见,与健康对照无差异。

研究设计与样本

  • 纵向队列研究,采用酶联免疫吸附试验检测抗皮质蛋白自身抗体滴度。
  • 纳入670例成人肌炎患者、343例幼年肌炎患者、202例成人健康对照和90例幼年健康对照。

主要发现

  • 成人皮肌炎患者抗皮质蛋白抗体患病率为15%(P=0.005),合并抗Mi-2者为24%(P=0.03),合并抗NXP-2者为23%(P=0.04)。
  • 成人肌炎中,抗皮质蛋白阳性者皮肤受累占62%对比阴性者38%(P=0.03),吞咽困难占36%对比17%(P=0.02)。
  • 成人肌炎中,抗皮质蛋白阳性者合并抗Ro52占47%对比26%(P=0.001),合并抗NT5c1a占59%对比33%(P=0.001)。
  • 间质性肺病患者抗皮质蛋白抗体滴度更高(0.15对比0.12任意单位,P=0.03)。
  • 幼年肌炎中抗皮质蛋白抗体患病率为2%,与幼年健康对照的4%无差异;阳性者「机械手」占25%对比7%(P=0.03),住院次数2.9对比1.3(P=0.04),峰值肌酸激酶368对比818 IU/L(P=0.02)。

临床怎么用

  • 成人皮肌炎患者可检测抗皮质蛋白抗体,尤其合并抗Mi-2或抗NXP-2抗体时。
  • 成人肌炎抗皮质蛋白抗体阳性提示需关注吞咽困难和间质性肺病。
  • 幼年肌炎中该抗体检测价值有限,阳性者需关注「机械手」和住院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis. METHODS: In this longitudinal cohort study, anti-cortactin autoantibody titers were assessed by enzyme-linked immunosorbent assay in 670 adult myositis patients and 343 juvenile myositis patients as well as in 202 adult healthy controls and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. Clinical features of patients with and those without anti-cortactin autoantibodies were also compared. RESULTS: Anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%; P = 0.005), particularly those with coexisting anti-Mi-2 autoantibodies (24%; P = 0.03) or anti-NXP-2 autoantibodies (23%; P = 0.04). In adult myositis, anti-cortactin was associated with DM skin involvement (62% of patients with anti-cortactin versus 38% of patients without anti-cortactin; P = 0.03), dysphagia (36% versus 17%; P = 0.02) and coexisting anti-Ro 52 autoantibodies (47% versus 26%; P = 0.001) or anti-NT5c1a autoantibodies (59% versus 33%; P = 0.001). Moreover, the titers of anti-cortactin antibodies were higher in patients with interstitial lung disease (0.15 versus 0.12 arbitrary units; P = 0.03). The prevalence of anti-cortactin autoantibodies was not different in juvenile myositis patients (2%) or in any juvenile myositis subgroup compared to juvenile healthy controls (4%). Nonetheless, juvenile myositis patients with these autoantibodies had a higher prevalence of "mechanic's hands" (25% versus 7%; P = 0.03), a higher number of hospitalizations (2.9 versus 1.3; P = 0.04), and lower peak creatine kinase values (368 versus 818 IU/liter; P = 0.02) than those without anti-cortactin. CONCLUSION: The prevalence of anti-cortactin autoantibodies is increased in adult DM patients with coexisting anti-Mi-2 or anti-NXP-2 autoantibodies. In adults, anti-cortactin autoantibodies are associated with dysphagia and interstitial lung disease.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Pinal-Fernandez I, Pak K, Gil-Vila A, et al. Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis Rheumatol. 2021. PMID: 34313394. doi:10.1002/art.41931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。